# Evaluate the Safety and Efficacy of Caspofungin Acetate as Empirical Therapy in Chinese Adults With Persistent Fever and Neutropenia (0991-055)

> **NCT00548080** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 131 (actual)

## Conditions studied

- Fungal Infection

## Interventions

- **DRUG:** MK0991, caspofungin acetate / Duration of Treatment:

## Key facts

- **NCT ID:** NCT00548080
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-03
- **Primary completion:** 2006-11
- **Final completion:** 2006-11
- **Target enrollment:** 131 (ACTUAL)
- **Last updated:** 2015-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00548080

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00548080, "Evaluate the Safety and Efficacy of Caspofungin Acetate as Empirical Therapy in Chinese Adults With Persistent Fever and Neutropenia (0991-055)". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00548080. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*